Log in with your email address username.

×

[Comment] Renal denervation in uncontrolled hypertension: the story continues to unfold

In The Lancet David E Kandzari and colleagues report the 6 month efficacy and safety results from the randomised, single-blind, sham-controlled SPYRAL HTN-ON MED proof-of-concept trial.1 The investigators noted that on average renal denervation had a blood pressure lowering effect in patients with uncontrolled hypertension who were on antihypertensive medication.1 Office and 24 h ambulatory blood pressure decreased significantly from baseline to 6 months in the renal denervation group (mean baseline-adjusted treatment differences in 24 h systolic blood pressure −7·0 mm Hg, 95% CI −12·0 to −2·1, p=0·0059; 24 h diastolic blood pressure −4·3 mm Hg, −7·8 to −0·8, p=0·0174; office systolic blood pressure −6·6 mm Hg, −12·4 to −0·9, p=0·0250; and office diastolic blood pressure −4·2 mm Hg, −7·7 to −0·7, p=0·0190).

email